Levosimendan API Manufacturers

compare suppliers & get competitive offers

Filters

Reset

Selected filters:

Type
Production region
Qualifications
Country of origin

HIGHLIGHTED

Located in:

Spain

Producer

Produced in:

Spain

Established in: 1993

MOQ: 10 kg

Employees: 700+

We can develop new APIs upon request

GMP, EMA/FDA, OSHAS cert. CDMO

12 local offices, strategically around the world

  • CoA

  • GMP

  • CEP

  • FDA

  • DMF

  • + 0

All certificates

  • CEP

  • GDP

  • DMF

  • GMP

  • CoA

  • ISO9001

Contact supplier

Replies quickly

Produced in:

China

Established in: 2012

MOQ: 1 kg

Employees: 500+

GMP and ISO14001 certified manufacturing sites

Robust R&D team with 300+ professionals

Modern high-tech pharmaceutical enterprise

  • CoA

  • GMP

  • CEP

  • FDA

  • DMF

  • + 0

All certificates

  • CoA

  • WC

  • MSDS

  • BSE/TSE

  • DMF

  • GMP

Contact supplier

Replies quickly

Located in:

Spain

Producer

  • CoA

  • GMP

  • CEP

  • FDA

  • DMF

  • + 0

All certificates

  • GMP

  • CoA

Contact supplier

Replies slower than most

Located in:

Finland

Producer

  • CoA

  • GMP

  • CEP

  • FDA

  • DMF

  • + 0

All certificates

  • DMF

  • CoA

Located in:

Italy

How does it work?

1
Register for free
icon

You can register for free as long as you are registering on behalf of a legal company related to the pharmaceutical industry

2
Start sourcing
icon

Search in the search bar the product that you’re looking for. We’ll show you an overview of all available suppliers. Use the filters to select the relevant suppliers only

3
Send inquiries
icon

Have you found interesting suppliers? Then it’s time to contact them. Use the send inquiry button and send them a message. You can send for each product, 3 inquiries per week

4
Get quotation
icon

Suppliers get notified by Pharmaoffer that they’ve received a new inquiry. They will come back to you with their questions, certificates, and offer in the chat on Pharmaoffer. We will send you an email in case of any news

5
Arrange agreement
icon

Does the supplier meet your quality and commercial requirements? Then you can place the order. Just follow the steps of our order module

Looking for Levosimendan API 141505-33-1?

Description:
Here you will find a list of producers, manufacturers and traders of Levosimendan. You can sort by certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
API | Excipient name:
Levosimendan 
Synonyms:
Levosimedan , Levosimendanum , Simdax  
Cas Number:
141505-33-1 
DrugBank number:
DB00922 
Unique Ingredient Identifier:
C6T4514L4E

About Levosimendan

Why are professionals looking for Levosimendan? Levosimendan increases calcium sensitivity to myocytes by binding to troponin C in a calcium dependent manner. This increases contractility without raising calcium levels. It also relaxes vascular smooth muscle by opening adenosine triphosphate sensitive potassium channels. Levosimendan is used to manage acutely decompensated congestive heart failure.

More information such as the structure, indication or toxicity is available on Drugbank, click the ID above.

Levosimendan is a type of Calcium regulators


Calcium regulators are a vital subcategory of pharmaceutical Active Pharmaceutical Ingredients (APIs) used in the field of medicine. These compounds play a crucial role in maintaining the balance of calcium levels within the body. Calcium is an essential mineral that participates in numerous physiological processes, including muscle contraction, nerve transmission, and bone health.

Pharmaceutical APIs classified as calcium regulators are designed to modulate the levels of calcium in the body, either by increasing or decreasing its concentration as needed. These APIs act by targeting specific mechanisms involved in calcium regulation, such as calcium channels, transporters, or enzymes.

Calcium regulators find application in the treatment of various medical conditions. For instance, drugs that promote calcium absorption or enhance bone mineral density can be employed to manage osteoporosis, a condition characterized by weak and brittle bones. Conversely, medications that inhibit calcium channels or reduce calcium levels are used in the treatment of conditions like hypertension or cardiac arrhythmias.

The development of calcium regulators involves extensive research and rigorous testing to ensure their safety and efficacy. Pharmaceutical companies invest significant resources in the discovery, synthesis, and optimization of these APIs. Additionally, regulatory authorities closely monitor the production and distribution of calcium regulators to ensure compliance with stringent quality standards.

In summary, calcium regulators are a specialized category of pharmaceutical APIs that play a crucial role in maintaining calcium balance within the body. These compounds are integral to the treatment of various medical conditions and require rigorous research and testing to ensure their effectiveness and safety.


Levosimendan (Calcium regulators), classified under Metabolic Bone Disease Agents


Metabolic Bone Disease Agents are a category of pharmaceutical active pharmaceutical ingredients (APIs) that are specifically designed to treat and manage conditions related to the bones and their metabolism. These agents play a crucial role in the treatment of various metabolic bone diseases, including osteoporosis, Paget's disease, and rickets.

The primary function of Metabolic Bone Disease Agents is to regulate bone remodeling and maintain bone health. They achieve this by targeting specific pathways involved in bone metabolism, such as osteoclast and osteoblast activity, calcium regulation, and vitamin D metabolism.

These APIs are commonly used in the development of medications, including oral tablets, injectables, and topical formulations, for the effective treatment of metabolic bone diseases. They are carefully formulated to optimize their pharmacokinetic and pharmacodynamic properties, ensuring maximum efficacy and minimal side effects.

Metabolic Bone Disease Agents encompass a range of substances, including bisphosphonates, selective estrogen receptor modulators (SERMs), calcitonin, and vitamin D analogs. These APIs act through different mechanisms to address specific aspects of bone health, such as inhibiting bone resorption, promoting bone formation, or regulating calcium levels.

In conclusion, Metabolic Bone Disease Agents are a vital category of pharmaceutical APIs used in the development of medications for the treatment and management of various metabolic bone diseases. These agents target specific pathways involved in bone metabolism to regulate bone remodeling, enhance bone health, and alleviate the symptoms associated with these conditions.



Levosimendan manufacturers | traders | suppliers

We have 5 companies offering Levosimendan produced in 4 different countries.

Get in contact with the supplier of your choice:

  • Suanfarma from Spain, product country of origin Spain
  • Shandong Loncom Pharmaceutical CO.,Ltd. from China, product country of origin China
  • Kinsy from Spain, product country of origin Spain
  • Fermion from Finland, product country of origin Finland
  • Edmond Pharma (Recipharm) from Italy, product country of origin Italy

Let the supplier know whether you are looking for a product with a specific monograph such as EP (Ph. Eur.), USP, JP, BP or another quality. Or, whether you are looking for hydrochloride (HCl), anhydricum, base, micronisatum or a specific purity.

You can use the filters to find high-quality suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our FAQ page or use the chat box in the corner to get more information about Pharmaoffer.